可溶性触发受体表达于髓样细胞2（TREM2）与阿尔茨海默病及轻度认知障碍的关联：一项系统评价和荟萃分析。

Association of soluble TREM2 with Alzheimer's disease and mild cognitive impairment: a systematic review and meta-analysis.

作者信息

Wang Ruiqi, Zhan Yijun, Zhu Wenyan, Yang Qianwen, Pei Jian

机构信息

Department of Acupuncture, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.

出版信息

Front Aging Neurosci. 2024 May 22;16:1407980. doi: 10.3389/fnagi.2024.1407980. eCollection 2024.

DOI:10.3389/fnagi.2024.1407980

PMID:38841103

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11150578/

Abstract

OBJECTIVE

Soluble triggering receptor expressed on myeloid cells 2 (sTREM2) is a potential neuroinflammatory biomarker linked to the pathogenesis of Alzheimer's disease (AD) and mild cognitive impairment (MCI). Previous studies have produced inconsistent results regarding sTREM2 levels in various clinical stages of AD. This study aims to establish the correlation between sTREM2 levels and AD progression through a meta-analysis of sTREM2 levels in cerebrospinal fluid (CSF) and blood.

METHODS

Comprehensive searches were conducted in PubMed, Embase, Web of Science, and the Cochrane Library to identify observational studies reporting CSF and blood sTREM2 levels in AD patients, MCI patients, and healthy controls. A random effects meta-analysis was used to calculate the standardized mean difference (SMD) and 95% confidence intervals (CIs).

RESULTS

Thirty-six observational studies involving 3,016 AD patients, 3,533 MCI patients, and 4,510 healthy controls were included. CSF sTREM2 levels were significantly higher in both the AD [SMD = 0.28, 95% CI (0.15, 0.41)] and MCI groups [SMD = 0.30, 95% CI (0.13, 0.47)] compared to the healthy control group. However, no significant differences in expression were detected between the AD and MCI groups [SMD = 0.09, 95% CI (-0.09, 0.26)]. Furthermore, increased plasma sTREM2 levels were associated with a higher risk of AD [SMD = 0.42, 95% CI (0.01, 0.83)].

CONCLUSION

CSF sTREM2 levels are positively associated with an increased risk of AD and MCI. Plasma sTREM2 levels were notably higher in the AD group than in the control group and may serve as a promising biomarker for diagnosing AD. However, sTREM2 levels are not effective for distinguishing between different disease stages of AD. Further investigations are needed to explore the longitudinal changes in sTREM2 levels, particularly plasma sTREM2 levels, during AD progression.

SYSTEMATIC REVIEW REGISTRATION

https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024514593.

摘要

目的

髓系细胞触发受体2（sTREM2）是一种潜在的神经炎症生物标志物，与阿尔茨海默病（AD）和轻度认知障碍（MCI）的发病机制相关。以往研究关于AD不同临床阶段的sTREM2水平得出了不一致的结果。本研究旨在通过对脑脊液（CSF）和血液中sTREM2水平的荟萃分析，确定sTREM2水平与AD进展之间的相关性。

方法

在PubMed、Embase、Web of Science和Cochrane图书馆进行全面检索，以识别报告AD患者、MCI患者和健康对照者脑脊液和血液中sTREM2水平的观察性研究。采用随机效应荟萃分析计算标准化平均差（SMD）和95%置信区间（CI）。

结果

纳入了36项观察性研究，涉及3016例AD患者、3533例MCI患者和4510例健康对照者。与健康对照组相比，AD组[SMD = 0.28，95% CI（0.15，0.41）]和MCI组[SMD = 0.30，95% CI（0.13，0.47）]的脑脊液sTREM2水平均显著升高。然而，AD组和MCI组之间未检测到表达上的显著差异[SMD = 0.09，95% CI（-0.09，0.26）]。此外，血浆sTREM2水平升高与AD风险增加相关[SMD = 0.42，95% CI（0.01，0.83）]。